FASgen Announces A New Discovery In Obesity Research

FASgen is pleased to report the publication of important new research results in the obesity field using FAS89B, one of the Company’s proprietary compounds. FASgen is a leader in the field of research into selective inhibition of fatty acid synthase (FASi), and has conducted extensive research in the area of metabolic disease disorders, specifically for the treatment of obesity and fatty liver disease. [click link for full article]

More: continued here

Filed under: Obesity / Weight Loss / Fitness on December 24th, 2007